Navigation Links
Double Eagle Holdings Chooses National Securities Corporation as Exclusive Investment Banker
Date:8/15/2011

AVENTURA, Fla., Aug. 15, 2011 /PRNewswire/ -- Double Eagle Holdings, Ltd (OTCQB: DEGH), announced today that it has retained National Securities Corporation as the company's exclusive investment banker to lead the company's next round of capitalization, as well as possible acquisition and strategic alliance transactions. Double Eagle Holdings is the parent company of Fuse Science, Inc. (www.fusescience.com), the developer of new, proprietary technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.

Founded in 1947, National Securities Corporation is an international full service independent brokerage firm with a diverse base of retail and institutional clients. National Securities was founded in 1947 in Seattle, Washington with the goal of providing a full suite of financial products and services to its registered representatives and clients. National Securities and its subsidiaries are headquartered in New York City and Seattle and have a multitude of domestic and international offices that provide a broad range of securities brokerage, financial planning, and investment services, as well as corporate finance and investment banking services to corporations and businesses. The company operates in more than 70 locations throughout the United States and Europe through some 800 Registered Representatives.(www.nationalsecurities.com/investmentbanking.php)

Fuse Science just recently announced its strategy to advance its technology through several major categories ranging from energy drinks to aspirin and from vitamins to major pharmaceutical applications in partnership with the New England Consulting Group.

"We believe in recruiting the best for all facets of our business, and National Securities is a proven leader in working with emerging growth companies," added Brian Tuffin, Fuse Science President and Chief Operating Officer. "As an immediate priority, the National Securities team will lead our company's next round of financing, which will fully capitalize operations through our next stage of growth and allow us to bring Fuse Science's ground-breaking technology to market."

About Double Eagle Holdings

Double Eagle Holdings (OTCQB: DEGH.pk) is an innovative consumer products holding company and the parent company of Fuse Science, Inc. Based in Aventura, Florida, Fuse Science is the developer of patent-pending conveyance technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, delivering their benefits faster and more effectively than ever before. Information about Fuse Science is available online at www.fusescience.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the company's SEC filings. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.


'/>"/>
SOURCE Double Eagle Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
2. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
3. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
4. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
5. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
6. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
7. Gaining Too Much Weight During Pregnancy Nearly Doubles Risk of Having a Heavy Baby
8. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
9. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
10. Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
11. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):